Selank is a heptapeptide. That is a peptide built from seven amino acids (sequence TKPRPGP). This is an identity fact, not a Form Labs product claim.
Selank sequence identity (TKPRPGP)Plain-English research guideTP-7 / TKPRPGP
Selank research guide
Everything worth knowing, without the jargon.
Selank is a synthetic heptapeptide (seven amino acids, sequence TKPRPGP; research name TP-7) developed in Russia at the Institute of Molecular Genetics, Russian Academy of Sciences, as a tuftsin analog with a Pro-Gly-Pro tail.
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
REV 2026-10 · 1 Oct 20265 peer-reviewed studiesResearch-use-only context
What the papers reportThird-party literature - not product claims
The first four amino acids, TKPR, match the tuftsin pattern. This is a structure record, not a Form Labs product claim.
Koroleva and Myasoedov, Biology Bulletin, 2019Genes linked to inflammation with changed activity in mouse spleen in the 2011 Kolomin lab study. This is a mouse-tissue finding, not a Form Labs product claim.
Kolomin et al., Regulatory Peptides, 2011Why it matters
Why is Selank studied?
Selank is a heptapeptide. This means it is a lab-made peptide with seven amino acids, in the order TKPRPGP (Form Labs catalogue record). Researchers at the Institute of Molecular Genetics, Russian Academy of Sciences, developed it in Russia. It is an analog of tuftsin, a natural immune peptide. Selank keeps the first four amino acids of tuftsin. It adds a Pro-Gly-Pro tail. Most of the evidence is animal and lab work. A few Russian clinical papers look at disorders linked to anxiety.
Mostly animal and laboratory research, plus Russian clinical records.
Researchers at the Institute of Molecular Genetics in Russia made Selank as a synthetic analog of tuftsin. Tuftsin is a short peptide that carries signals in the immune system. Its sequence is TKPR. Selank keeps those first four amino acids. It adds a Pro-Gly-Pro tail for stability. This gives the full sequence of seven amino acids, TKPRPGP.
The evidence looks different from a Western drug development programme. It includes Russian clinical papers on disorders linked to anxiety. It includes animal and cell work on GABA and monoamine systems. It includes immune papers on cytokines and inflammation genes. It also includes lab studies of enzymes. This guide uses these records as research context only. They are not product claims or use guidance.
Study observations
What laboratory observations have Selank studies reported?
Selank was tested in animal tissue. Volkova et al. (2016) reported changed activity in genes for brain signalling in rat brain tissue. Kolomin et al. (2011) reported changed activity in genes for inflammation in mouse spleen. Both are animal lab findings. A third study looked at enzymes in human blood serum. That study is lab chemistry. None of this shows clinical results for the Form Labs material.
Selank laboratory measurements Findings stay tied to the cited study and its model.
Peptide identity
The Form Labs catalogue record names Selank as TKPRPGP. It is a tuftsin analog with a Pro-Gly-Pro tail.
Rat brain tissue
Volkova et al. (2016) reported changed activity in genes linked to brain signalling in rat brain tissue. These are lab observations.
Mouse spleen tissue
Kolomin et al. (2011) reported changed activity in genes linked to inflammation in mouse spleen. This is an animal finding.
Pharmacology at a glance
- Research code
- TKPRPGP (TP-7)
- Class
- A synthetic tuftsin analog. The first four amino acids match tuftsin (TKPR). A Pro-Gly-Pro tail is added for stability.
- Molecule
- A synthetic heptapeptide (seven amino acids). CAS 129954-34-3, molecular formula C33H57N11O9, molecular weight about 751.9 g/mol.
- Reported half-life
- No clean half-life is quoted here. The literature talks about design for stability and about enzymes in human serum that break down enkephalin.
- Originator
- Institute of Molecular Genetics, Russian Academy of Sciences (Russia)
- Approval status
- Developed and used in Russia as an anxiolytic. Sold in Russian pharmacies. The TGA (Australia) and the FDA (US) have not approved it. It has no marketing authorisation in the EU.
What it has been studied for
What has Selank been studied for?
Selank research includes a Russian clinical study in patients with generalized anxiety disorder or neurasthenia (Zozulya et al., 2008). It includes changed gene activity in rat brain tissue (Volkova et al., 2016). It also includes gene tests in mouse spleen (Kolomin et al., 2011). The animal and lab findings stay apart from the clinical study.
Study areas from the published literature.
Anxiety-related behaviour and clinical scales
Studied in the Russian clinical study of 62 patients. It tracked rating scales and enkephalin activity in blood serum.
Zozulya et al., Zhurnal Nevrologii i Psikhiatrii, 2008Immune and cytokine markers
Studied for immune markers. These include IL-6, T-helper cytokine balance, IFN-alpha, and genes linked to inflammation.
Uchakina et al., Zhurnal Nevrologii i Psikhiatrii, 2008; Kolomin et al., Regulatory Peptides, 2011GABA and monoamine systems
Lab and animal studies look at how it interacts with GABA receptors. They also look at genes linked to brain signalling.
Vyunova et al., Neurochemical Journal, 2014; Volkova et al., Frontiers in Pharmacology, 2016BDNF marker context
Discussed in the Selank physiology literature as a nerve growth marker. This guide does not quote a standalone human BDNF result.
Koroleva and Myasoedov, Biology Bulletin, 2019Enkephalin-degrading enzymes
Kost et al. (2001) reported that Selank blocks enzymes in human serum that break down enkephalin. This is a lab chemistry finding.
Kost et al., Russian Journal of Bioorganic Chemistry, 2001The studies
What did the Selank studies find?
The five Selank studies in this guide are one Russian human study and four lab studies. Zozulya et al. (2008) studied 62 patients with generalized anxiety disorder or neurasthenia. They compared Selank with medazepam. Kolomin et al. (2011) reported that 34 of 84 genes linked to inflammation changed in mouse spleen. This guide draws no conclusion about how well Selank works from the human study. It does not treat the study as a Western regulatory trial.
Open any study for a plain summary, what it measured, the finding, and a link to the paper.
Zozulya et al. (2008) compared Selank with medazepam over 14 days. They studied 62 patients with generalized anxiety disorder or neurasthenia.
- Studied in
- 62 patients with generalized anxiety disorder or neurasthenia.
- Design
- A 14-day clinical comparison with 30 patients in the Selank group and 32 in the medazepam group (Zozulya et al., 2008).
- Measured
- Psychometric scales and serum enkephalin activity.
This is the human anchor for Selank in the Russian literature (Zozulya et al., 2008). The study records a group, a comparator, scales, and serum enkephalin activity. This guide draws no conclusion about how well Selank works. It does not treat the study as a Western regulatory trial.
DOI https://pubmed.ncbi.nlm.nih.gov/18454096/A rat frontal-cortex study. It measured the activity of genes linked to brain signalling after Selank exposure.
- Studied in
- Rat frontal cortex.
- Design
- A lab study in animals that looked at 84 genes linked to brain signalling.
- Measured
- Activity of genes linked to GABA and monoamine signalling.
Volkova et al. (2016) reported changed activity in genes linked to brain signalling in rat brain tissue. This is an animal lab finding. It is not a claim about mood, anxiety, thinking or any person.
DOI 10.3389/fphar.2016.00031A lab study of how Selank interacts with GABA receptors. These sit on the outer membrane of nerve cells.
- Studied in
- Nerve-cell plasma membranes.
- Design
- A study of how Selank binds to and interacts with receptors.
- Measured
- Context on how it interacts with and binds to GABA receptors.
The paper is a narrow record of GABA receptor binding (Vyunova et al., 2014). It is not a claim that Selank changes anxiety, mood or thinking in people.
DOI 10.1134/S1819712414040114A mouse-spleen study. It measured the activity of genes linked to inflammation after Selank, in an IFN-alpha context.
- Studied in
- Mouse spleen tissue.
- Design
- A lab study of the activity of 84 genes linked to inflammation.
- Measured
- How many genes linked to inflammation changed in activity, and which ones.
Kolomin et al. (2011) reported that 34 of 84 genes linked to inflammation changed in activity in mouse spleen. This is a mouse-tissue lab finding. It is not a Form Labs product claim.
DOI 10.1016/j.regpep.2011.05.001A lab chemistry study of Semax and Selank. It looked at how they interact with enzymes in human serum. These enzymes break down enkephalin.
- Studied in
- Human serum enzyme assays.
- Design
- A test-tube study of enzymes.
- Measured
- Blocking of the enzymes that break down enkephalin.
Kost et al. (2001) reported that Semax and Selank block the enzymes in human serum that break down enkephalin. This is lab chemistry. It is not a claim about what the Form Labs material does in a person.
DOI 10.1023/A:1011373002885Where evidence stops
What has Selank research not established?
The Selank studies in this guide are lab work and one Russian clinical study (Zozulya et al., 2008). They are not a Western Phase 1-3 programme. The research gives no directions for use in or on people or animals. It describes the molecule in general. It does not say what one batch does.
- Large Western clinical trials: no Phase 1-3 programme has been reviewed by the TGA, FDA or EU regulators.
- Any use in or on people or animals: none of the research on this page is a use direction.
- What a specific batch does: the studies are about the molecule in general, not this vial.
Development and status
Is Selank approved, and where does the research stand?
This guide does not state Selank's approval status. Its sources hold no regulator record of an approval decision. The research timeline starts with work on enzymes that break down enkephalin (Kost et al., 2001). Next comes a Russian clinical study in 62 patients (Zozulya et al., 2008). It ends with a review of Selank structure and physiology (Koroleva and Myasoedov, Biology Bulletin, 2019).
The Institute of Molecular Genetics makes Selank as a tuftsin analog. It has a Pro-Gly-Pro tail.
Kost and colleagues report lab chemistry work. Semax and Selank block enzymes in human serum that break down enkephalin.
Zozulya and colleagues publish a Russian clinical study. It had 62 patients.
Uchakina and colleagues publish immune marker work. It covers IL-6 and T-helper cytokine balance in anxiety-asthenic disorders.
Kolomin and colleagues report a Regulatory Peptides study. In mouse spleen, 34 of 84 genes linked to inflammation changed.
Vyunova and colleagues publish work in Neurochemical Journal. It covers how Selank interacts with GABA receptors.
Volkova and colleagues publish work in Frontiers in Pharmacology. It covers gene activity in the rat frontal cortex.
Koroleva and Myasoedov publish a review in Biology Bulletin. It covers Selank structure and physiology.
Approval status: Developed and used in Russia as an anxiolytic. Sold in Russian pharmacies. The TGA (Australia) and the FDA (US) have not approved it. It has no marketing authorisation in the EU.Whatever the molecule’s status elsewhere, what Form Labs supplies is research-use-only reference material - for laboratory work, not for people or animals.
Evidence and limitations
What does the Selank research mean, and what does it not?
Most Selank evidence is animal, cell, immune and lab chemistry work. The one human anchor is a Russian clinical study (Zozulya et al., 2008). It looked at disorders linked to anxiety. It is not a Western drug development programme. The 62-patient study gives size and comparator context. This guide does not claim that Selank treats anything. It does not claim that Selank changes mood in people.
Mostly animal and laboratory research, plus Russian clinical literature
Most of the Selank evidence is animal, cell, immune and lab chemistry work. The one human anchor is Russian clinical work on disorders linked to anxiety. It is not a Western drug development programme.
No TGA or FDA approval, no EU marketing authorisation
Selank was developed and used in Russia as an anxiolytic. It is sold in Russian pharmacies. The TGA (Australia) and the FDA (US) have not approved it. It has no marketing authorisation in the EU. Do not read anything here as Western regulatory approval.
The 62-patient record is not an efficacy claim
The Zozulya study gives the human study size and comparator context. This guide does not claim that Selank treats disorders linked to anxiety. It does not claim that Selank changes mood in people.
Where Form Labs fits
This guide is a plain-English summary of published research. Form Labs did not run that research. It is not medical advice, not a product claim and not use guidance. Form Labs supplies Selank strictly as reference material, with a catalog lot record, for lab research.
Lab handling
How is Selank handled as reference material?
Selank is lab reference material. It is not for human consumption or veterinary use. Storage and lot checks follow the product label and any verified matching certificate of analysis (COA). This guide's catalogue record notes storage at 2-8 C and protection from light.
Research-use boundary
Selank is supplied strictly for lab research. It is not for human, veterinary, medical, cosmetic or any other use.
COA and label
Each lab report covers only the sample, amount and lot it names. Match the lot number on your vial to the reports in the certificate library.
Storage
Supplied freeze-dried. Keep it at 2-8°C (fridge-cold) and out of light. Follow the vial label, any verified matching lab report for the batch. The receiving lab's own written procedures.
Glossary
Plain-English definitions.
- Heptapeptide
- A peptide made from seven amino acids. Selank's sequence is TKPRPGP.
- TP-7
- A research name used for Selank in the literature.
- Tuftsin
- A natural peptide of four amino acids, Thr-Lys-Pro-Arg, written TKPR.
- Tuftsin analog
- A lab-made peptide designed around the sequence of tuftsin. Selank keeps TKPR and adds Pro-Gly-Pro.
- Pro-Gly-Pro tail
- The last three amino acids in Selank's sequence. The literature says this tail helps stability.
- BDNF
- Brain-derived neurotrophic factor. It is a protein that researchers measure as a nerve growth marker.
- GABA
- A signalling molecule. This guide names it only in research on receptor interaction and brain-signalling genes.
- Monoamine
- A group of signalling chemicals that includes dopamine and serotonin.
- Cytokine
- A signalling protein of the immune system. Some Selank immune papers measure it.
- Research use only (RUO)
- A lab-only boundary. It means not for human consumption, or for veterinary, medical or cosmetic use.
FAQ
What are the most common questions about Selank?
Selank is a heptapeptide with the sequence TKPRPGP (Form Labs catalogue record). It was developed in Russia as an analog of the natural peptide tuftsin. Most of the research is on animals and cells. The common questions cover its sequence and what it is studied for. They also cover whether it is a nootropic or anxiolytic, how it differs from Semax, and its Australian status. Form Labs supplies reference material for research use only.
Selank is a heptapeptide. That means it is a peptide of seven amino acids, with the sequence TKPRPGP. It was developed in Russia at the Institute of Molecular Genetics. It is an analog of the natural peptide tuftsin. Published research studies it for behaviour linked to anxiety and for immune markers (cytokines). Most of this is animal work, plus some Russian clinical research. Form Labs supplies Selank strictly as reference material for research use only. It is not for human or veterinary use.
Selank's sequence is TKPRPGP (Thr-Lys-Pro-Arg-Pro-Gly-Pro). It is a heptapeptide built as an analog of tuftsin. The first four amino acids match the tuftsin fragment (Thr-Lys-Pro-Arg). A Pro-Gly-Pro tail makes the peptide more stable. Research also lists it as TP-7. Its chemical registry number is CAS 129954-34-3. Its molecular formula is C33H57N11O9. Its molecular weight is about 751.9 g/mol.
Research studies Selank for behaviour linked to anxiety. It also covers BDNF markers and GABA binding. It covers immune and cytokine markers, and serotonin or monoamine systems. The records are mostly animal, cell, immune and lab chemistry studies, plus Russian clinical work. They are research context only. They are not Form Labs product claims or use guidance.
Zozulya et al. (2008) recorded clinical scales and serum enkephalin activity. The patients had generalized anxiety disorder or neurasthenia. Volkova et al. (2016) reported gene measures in rat brain tissue. These are different study settings. This guide draws no clinical conclusion for any one person from them.
Selank and Semax are two different synthetic peptides. Selank has the sequence TKPRPGP. It is an analog of the peptide tuftsin. It is studied more in anxiety and immune marker research. Semax has the sequence MEHFPGP. It is an analog of a fragment of the hormone ACTH. It is studied mostly in neuroprotection and thinking research. Form Labs supplies both for research use only.
Selank is a tuftsin analog. Its first four amino acids match tuftsin's TKPR sequence. The peptide adds a Pro-Gly-Pro tail. Published research discusses BDNF as a nerve growth marker. It also discusses immune markers. These include IL-6, T-helper cytokine balance, IFN-alpha, and the activity of genes linked to inflammation. These are lab and literature measures.
Selank is developed and used in Russia as an anxiolytic. It is sold in Russian pharmacies. The Therapeutic Goods Administration (TGA) in Australia and the FDA in the United States have not approved it. It has no marketing authorisation in the European Union. Form Labs supplies it for research use only. It is not a medicine and not for human or veterinary use.
Selank has no individual entry in the October 2026 Poisons Standard (checked 1 October 2026), and absence from that document is never a permission. Form Labs supplies Selank strictly as laboratory research material, not for human or veterinary use.
Selank is supplied strictly as lab research material. This guide is a plain-English summary of published research. Form Labs did not run that research. It is not medical advice, not a product claim, and not guidance for any human or veterinary use.
Selank is supplied freeze-dried. The handling notes call for storage at 2-8°C (fridge-cold), protected from light. Orders use Form Labs' standard bank-transfer prepay flow. Shipping is AU-only from Perth by Australia Post or CouriersPlease. Standard costs $10 and takes 5-7 days. Express costs $20 and takes 2-3 business days. Orders over $200 get free standard shipping and a free BAC Water. Orders over $300 get free Express. Tracking is emailed when the parcel is lodged.
References
Every figure, sourced.
Educational references to third-party literature. Form Labs is unaffiliated with the study authors.
Zozulya AA et al. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova, 2008 - 62 patients with generalized anxiety disorder or neurasthenia; Selank 30 versus medazepam 32; psychometric scales and serum enkephalin activity. PMID 18454096.
Uchakina ON et al. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova, 2008 - IL-6 and Th1/Th2 cytokine-balance context in anxiety-asthenic disorders. PMID 18577961.
Kolomin TA et al. Regulatory Peptides, 2011, 170(1-3):18-23 - mouse-spleen study of 84 inflammation genes, with 34 changed.
DOIVolkova A et al. Frontiers in Pharmacology, 2016, 7:31 - rat frontal-cortex study of 84 neurotransmission genes in GABAergic and monoamine context.
DOIVyunova TV et al. Neurochemical Journal, 2014, 8:259-264 - GABA ligand-receptor interaction and binding with nerve-cell plasma membranes.
DOIKost NV et al. Russian Journal of Bioorganic Chemistry, 2001, 27:156-159 - Semax and Selank inhibition of enkephalin-degrading enzymes of human serum.
DOIKoroleva SV and Myasoedov NF. Biology Bulletin, 2019, 46:407-414 - Selank structure and physiology review; general background context.
DOICitations are provided for education only. No therapeutic, weight-loss, or efficacy claims are made.
How we produce these guides
These guides are written and maintained in-house by the Form Laboratories research team. They summarise published literature and link to the cited papers. Form Laboratories did not run those studies. They are not authored by a named clinician and are not medical advice.
Findings remain tied to the study population, model and limits. Cell and animal observations remain separate from clinical results. Everything we supply is research-use-only reference material, not for people or animals.
The product
Form Laboratories - Selank
Ready to see Selank?
- Check available reports and the tests they cover.
- Compare the listed compound, amount and lot with the report.
- Ships from Perth via Australia Post or CouriersPlease in plain packaging.
Related catalogue records
Compare nearby catalogue records.
These nearby records stay inside the research-only catalogue.
Research-use-only catalogue
Continue to the product record.
Review lot-facing product details, pricing, and checkout boundaries on the matching product page.
View Selank - from $52.00 AUD